8-K: Glucotrack Completes Merger with Lokahi Therapeutics

Sentiment:

Merger and Financing Announcement 15 July 2026 5:20 PM

Glucotrack, Inc. has completed a strategic business combination with Lokahi Therapeutics, Inc., establishing a new public platform focused on healthcare asset development.

Capital raiseA private placement financing of approximately $4.45 million through the issuance of senior secured convertible promissory notes and warrants (Bridge Financing) was completed on July 14, 2026.The company plans a further private placement offering of up to $30,000,000 to strengthen its capital position.An ELOC Purchase Agreement with White Lion Capital, LLC allows for up to $50,000,000 in equity purchases over three years, subject to certain conditions and limitations.

Summary

Glucotrack, Inc. has merged with Lokahi Therapeutics, Inc., with Lokahi Therapeutics becoming the operating and controlling entity of the combined company.
The transaction aims to leverage Glucotrack's public market access and Lokahi's AI-driven asset sourcing and development platform.
Lokahi Therapeutics securityholders will hold approximately 90% of the combined company on a fully diluted basis after the preferred stock converts to common equity, subject to stockholder approvals and Nasdaq listing requirements.
A private placement financing is planned to strengthen the combined company's capital position.
Glucotrack's legacy continuous blood glucose monitoring (CBGM) technology will operate as a separate, wholly owned subsidiary.
Erik Emerson has been appointed CEO of the combined company, and Paul Goode will serve as Chief Technical Officer and CEO of the CBGM subsidiary.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive development, as the merger creates a new strategic direction and potential for growth, but significant execution risks and reliance on future financing remain.

Positives

Establishes a public platform for identifying, acquiring, and advancing healthcare assets.
Combines public market access with Lokahi's AI platform and operating model.
Strengthens the combined company's capital position through a planned private placement financing.
Maintains Glucotrack's CBGM business as a separate subsidiary for focused execution and strategic flexibility.
Unified leadership under new CEO Erik Emerson.

Negatives

The combined company's success is contingent on obtaining stockholder approvals and meeting Nasdaq listing requirements.
Potential for dilution to existing Glucotrack stockholders, as Lokahi securityholders are expected to hold 90% of the combined company.
The legacy Glucotrack CBGM technology will operate separately, potentially limiting immediate synergies.

Risks

Failure to obtain required stockholder approvals or satisfy Nasdaq continued listing standards.
Inability to consummate planned financings, including the private placement, on acceptable terms.
Integration challenges between Glucotrack and Lokahi Therapeutics.
Potential for adverse reactions or changes in business or employee relationships due to the transaction.
The combined company's capital structure and governance changes could negatively impact its securities' market value.
Risks associated with the continued development and commercialization of Glucotrack's CBGM technology.
The AI-driven asset sourcing and advancement platform's effectiveness is not guaranteed.

Future Outlook

The combined company aims to leverage its public market access and Lokahi's AI platform to identify, acquire, and advance differentiated healthcare assets, with a planned private placement to strengthen its capital position and support near-term execution. Glucotrack's CBGM technology will continue development within a dedicated subsidiary.

Management Comments

"This transaction establishes a capital-efficient, publicly listed platform designed to systematically identify, acquire, and advance differentiated healthcare assets," said Erik Emerson, Chief Executive Officer.
"By combining public market access with Lkahi Therapeutics ai platform and disciplined operating model, we are positioned to expand our pipeline, strengthen our capital structure, and pursue a broader set of strategic opportunities."
"This combination enables the continued advancement of Glucotracks core technology within a focused operating structure while participating in a broader platform designed for scalable growth. We believe this integrated approach supports disciplined execution across both operating priorities.", added Paul Goode, Chief Technical Officer.

Industry Context

StockSavvy.ai notes that this merger reflects a growing trend in the biopharmaceutical sector where companies are seeking to combine public market access with specialized technology platforms (like AI-driven asset sourcing) to accelerate growth and capital efficiency. The structure, where the acquired entity becomes the controlling business, is a strategic move to leverage existing public infrastructure while focusing on a specific development pipeline.

Comparison to Industry Standards

The structure of the merger, where Lokahi Therapeutics securityholders are expected to hold approximately 90% of the combined company, is a significant shift in control, often seen in reverse mergers or SPAC transactions aiming to inject new management and strategy into a public shell.
The planned private placement financing of up to $30 million is a common strategy to provide immediate working capital post-merger, aligning with industry practices for companies seeking to fund pipeline development and operational expansion.
The retention of Glucotrack's CBGM technology as a separate subsidiary is a strategic decision to isolate its specific development path and potential risks/rewards, a practice seen in diversified healthcare companies managing distinct business units.
The appointment of Erik Emerson, with extensive experience in the biopharmaceutical industry, as CEO aligns with industry standards for leadership in companies undergoing significant strategic shifts and aiming for pipeline advancement.

Management Changes

Role	Previous Person	New Person	Effective Date	Reason
Chief Executive Officer	Paul V. Goode	Erik Emerson	July 14, 2026	As contemplated in the Merger Agreement.
Member of the Board of Directors	Paul V. Goode	Erik Emerson	July 14, 2026	As contemplated in the Merger Agreement.
Chief Technical Officer	N/A	Paul Goode	July 14, 2026	Appointed as part of the merger.
Chief Executive Officer of CBGM subsidiary	N/A	Paul Goode	July 14, 2026	Appointed as part of the merger.

Corporate Governance

Change Type	Description	Effective Date	Impact Assessment
Board Size Expansion	The Acquiror Board expanded from five to six members.	July 9, 2026	Accommodates the appointment of Erik Emerson.
Certificate of Designation Filing	Filed Certificate of Designation for Series A Convertible Preferred Stock, later amended and restated.	July 9, 2026 and July 14, 2026	Defines the rights, preferences, and limitations of the Series A Convertible Preferred Stock.
Voting Support Agreement	Certain stockholders agreed to vote in favor of the Bridge Stockholder Approval, capital events, and meeting adjournments.	July 14, 2026	Ensures support for key transaction approvals.

Stakeholder Impact

Shareholders of Glucotrack: Potential dilution as Lokahi securityholders are expected to hold 90% of the combined company. However, the merger aims to create a stronger platform for future growth.
Shareholders of Lokahi Therapeutics: Gain access to a public market platform and potential for increased liquidity and capital access.
Employees: Potential for integration challenges and changes in roles, but also opportunities within a larger, combined entity.
Creditors: The company has assumed an existing note and entered into new financing agreements, impacting its debt structure.

Next Steps

Obtain required stockholder approvals for the merger and related matters.
Satisfy applicable Nasdaq listing requirements.
Complete the planned private placement financing.
Convert Series A Preferred Stock into Acquiror Common Stock.
Issue additional Acquiror Common Stock to existing stockholders if the Acquiror Stockholder Floor is not met post-conversion.
File a registration statement for resale of securities issued in the Bridge Financing.
File a proxy statement for stockholder approval of the Bridge Financing.

Key Dates

Date	Description
2025-09-12	Date of the Assumed Note.
2026-07-09	Date of Form 8-K filing and filing of Certificate of Designation of Series A Convertible Preferred Stock.
2026-07-14	Issuance Date of the Senior Secured Convertible Promissory Note; Closing Date of the Merger Agreement; Execution Date of the Purchase Agreement, Security Agreement, Voting Support Agreement, ELOC Purchase Agreement, and Registration Rights Agreement; Filing of Amended and Restated Certificate of Designation.
2026-08-30	Potential release date for a portion of the Subsidiary Contribution.

Recommendation

hold

The merger creates a new strategic direction with potential for growth, but significant execution risks, reliance on future financing, and dilution concerns warrant a 'hold' recommendation pending further operational and financial developments. The market will likely await evidence of successful integration and pipeline advancement.

Keywords

Glucotrack, Lokahi Therapeutics, Merger, Business Combination, Healthcare, Biopharmaceutical, Continuous Blood Glucose Monitoring, AI Platform

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.